anti-GPC3 CAR-T / AstraZeneca - LARVOL DELTA

Anti GPC3 CAR T lymphocytes effectively target NSCLC, including chemoresistant stem like cells (AACR 2026) - "GPC3 emerges as an effective and promising target for cell-based immunotherapy in lung cancer. Although preliminary, our data support the concept that anti-GPC3 CAR-T cells can effectively eliminate the CSC-enriched tumor compartment, which is believed to drive chemoresistance and recurrence, thus providing a rationale for future clinical development of cell-based immunotherapies in advanced or relapsed non-responsive lung cancer."

CAR T-Cell Therapy • IO biomarker • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • POU5F1